1Arnett FC, Edworthy SM, Block DA, et al. The ARA 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.
2Reboul P, Peletier JP, Tardif G, et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in the osteoarthritis. J Clin Invest,1996, 97: 2011-2019.
3Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloprotinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum, 2000, 43: 852-858.
4Cawston T, Billington C, Cleaver C, et al. The regulation of MMPs and TIMPs in cartilage turnover. Ann NY Acad Sci, 1999,878: 120-129.
5Ribbens C, Andre B, Jaspar J, et al. Matrix metalloproteinase-3serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol, 2000, 27: 888-893.
6Matrisian LM. The matrix-degrading metalloprotinases. Bioessays,1992, 14: 455-463.
7Kleiner DE, Tuuttila A, Tryggvason K, et al. Stability analysis of latent and active 72-kDa type Ⅳ collagenase: the role of tissue inhibitor of metalloproteinases-2 (RIMP-2). Biochemistry, 1993,32: 1583-1592.
8Myers A, Lakey R, Cawston TE, et al. Serum MMP-1 and TIMP1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology (Oxford), 2003, 42: 83-88.
9Tchetverikov I, Ronday HK, van EB, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis, 2004, 63: 881-883.
10Cunnane GM, Fitzgerald O, Beeton C, et al. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum, 2001, 44:2263-2274.
8Choy EH , Panayi CS. Cytokine pathway and joint inflammation in rheumatoid arthritis[ J]. New Engl J Med ,2001 ,344( 12 ) :907-916.
9Sharma K,Jin Y, Guo J, et al. Neutralization of TGF-beta by anti- TGF-beta Antibody attenuates kidney hypertrophy and the enhanced extra- cellular matrix gene expression in STZ- induced diabetic mice[ J]. Diabe- tes , 1996,45 (4) :522.
10Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognositic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis [ J ]. Arthritis Rheum, 2000, 43 ( 8 ) : 1831-1835.
